- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03798821
The Antioxidant Efficacy of a Product Probiotic in Research (BIO)
January 7, 2019 updated by: Francisco Javier López Román, Universidad Católica San Antonio de Murcia
Nutritional Clinical Trial to Evaluate the Antioxidant Efficacy of a Product Probiotic in Research
Determine the efficacy of the investigational product versus placebo in reducing stress oxidative during the performance of a physical exercise of a certain intensity and duration.
Study Overview
Status
Completed
Conditions
Detailed Description
The effectiveness of a probiotic for oxidative stress after eight weeks of the product to study will be checked.
the sample will be formed by cyclists that will submit to a baseline exercise and after the product is taken.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Murcia, Spain, 30107
- Catholic University of Murcia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age: between 18 and 45 years
- Sex: male, of Caucasian race, selected from the general population.
- Subjects that perform aerobic physical exercise between 2 and 4 times a week.
- Volunteers capable of understanding the clinical study, willing to grant consent informed in writing and to comply with the procedures and requirements of the study
Exclusion Criteria:
- Subjects with a history of any chronic disease.
- History of bronchial asthma or chronic obstructive pulmonary disease, disease Reactive airways such as bronchial asthma, a history of bronchial asthma or severe chronic obstructive pulmonary disease.
- Sinus bradycardia, second or third degree of atrioventricular block, insufficiency manifest cardiac or cardiogenic shock.
- History of allergic hypersensitivity or poor tolerance to any component of the products under study.
- Participation in another clinical trial in the three months prior to the study Lack of will or inability to comply with clinical trial procedures.
- Subjects diagnosed and / or under treatment for arterial hypertension.
- Smoking subjects (> 10 cigarettes a day).
- Subjects with body mass index greater than 35 Kg / m2 (BMI> 30).
- Subjects with a history of drug, alcohol or other substance abuse or other factors that limit their ability to cooperate during the study.
- Subjects whose condition does not make them eligible for the study according to the researcher's criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental
One capsule a day will be consumed.
At breakfast for the six weeks.
|
six weeks of consumption
six weeks of consumption
|
|
Placebo Comparator: Comparator
One capsule a day will be consumed.
At breakfast for the six weeks.
|
six weeks of consumption
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxidative damage to lipids
Time Frame: Oxidative lipid damage will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
It will be measured by isoprostanes in urine 24 hours.
|
Oxidative lipid damage will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxidative damage to DNA
Time Frame: Oxidative damage to DNA will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Analysis of 8-oxo 2'-deoxyguanosine in 24-hour urine.
|
Oxidative damage to DNA will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Oxidative damage to proteins.
Time Frame: Oxidative damage to protein will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Analysis of serum carbonyl groups
|
Oxidative damage to protein will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Oxidative damage to lipids
Time Frame: Oxidative damage to lipids will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
analysis of malondialdehyde in plasma
|
Oxidative damage to lipids will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Blood analysis
Time Frame: Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
serum carbonyls.
It is measured in nmol / mg proteins
|
Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Blood analysis
Time Frame: Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Malondialdehyde in plasma
|
Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Blood analysis
Time Frame: Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Oxidized LDL.
|
Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Blood analysis
Time Frame: Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Antioxidant capacity.
|
Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
|
Blood analysis
Time Frame: Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
glutathione metabolism.
It is measured in nmol / mg proteins
|
Blood analysis will be measured by the ELISA test on two different occasions. The measurements will be made at the beginning and at six weeks of consumption of the product.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2018
Primary Completion (Actual)
July 30, 2018
Study Completion (Actual)
January 4, 2019
Study Registration Dates
First Submitted
March 15, 2018
First Submitted That Met QC Criteria
January 7, 2019
First Posted (Actual)
January 10, 2019
Study Record Updates
Last Update Posted (Actual)
January 10, 2019
Last Update Submitted That Met QC Criteria
January 7, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCAM-CFE-0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.